BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33621692)

  • 21. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
    Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
    Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Klebsiella pneumoniae carbapenemase (KPC) producer resistant to ceftazidime-avibactam due to a deletion in the blaKPC3 gene.
    Antinori E; Unali I; Bertoncelli A; Mazzariol A
    Clin Microbiol Infect; 2020 Jul; 26(7):946.e1-946.e3. PubMed ID: 32061796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.
    García-Castillo M; García-Fernández S; Gómez-Gil R; Pitart C; Oviaño M; Gracia-Ahufinger I; Díaz-Regañón J; Tato M; Cantón R;
    Int J Antimicrob Agents; 2018 Mar; 51(3):511-515. PubMed ID: 29371104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detecting KPC-2 and NDM-1 Coexpression in Klebsiella pneumoniae Complex from Human and Animal Hosts in South America.
    Vásquez-Ponce F; Dantas K; Becerra J; Melocco G; Esposito F; Cardoso B; Rodrigues L; Lima K; de Lima AV; Sellera FP; Mattos R; Trevisoli L; Vianello MA; Sincero T; Di Conza J; Vespero E; Gutkind G; Sampaio J; Lincopan N
    Microbiol Spectr; 2022 Oct; 10(5):e0115922. PubMed ID: 35980188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of ceftazidime-avibactam and cefiderocol resistance in ST131-H30R1-
    Castillo-Polo JA; Hernández-García M; Maruri-Aransolo A; de la Vega C; Ruiz-Garbajosa P; Cantón R
    Microbiol Spectr; 2024 Apr; 12(4):e0277623. PubMed ID: 38415657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against
    Han R; Yang X; Yang Y; Guo Y; Yin D; Ding L; Wu S; Zhu D; Hu F
    Microbiol Spectr; 2022 Feb; 10(1):e0109221. PubMed ID: 35019685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
    Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants.
    Poirel L; Sadek M; Kusaksizoglu A; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):677-680. PubMed ID: 35088164
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Yu W; Xiong L; Luo Q; Chen Y; Ji J; Ying C; Liu Z; Xiao Y
    Front Cell Infect Microbiol; 2021; 11():780365. PubMed ID: 34900759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceftazidime-avibactam resistance in
    Arcari G; Polani R; Bruno F; Capitani V; Sacco F; Menichincheri G; Raponi G; Carattoli A
    Microb Genom; 2023 Feb; 9(2):. PubMed ID: 36752778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro effectiveness of ceftazidime-avibactam in combination with aztreonam on carbapenemase-producing Enterobacterales.
    Romina PE; Lucía A; Leticia C; Federica F; Pablo Á; Verónica S; Antonio G; Inés B; Rafael V
    J Glob Antimicrob Resist; 2023 Dec; 35():62-66. PubMed ID: 37611893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic evolution of ceftazidime-avibactam resistance due to interchanges between
    Chen Y; Yang R; Guo P; Liu P; Deng J; Wu Z; Wu Q; Huang J; Liao K
    Front Cell Infect Microbiol; 2023; 13():1244511. PubMed ID: 37671146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of anticancer chemotherapy on the extension of beta-lactamase spectrum: an example with KPC-type carbapenemase activity towards ceftazidime-avibactam.
    Hobson CA; Bonacorsi S; Hocquet D; Baruchel A; Fahd M; Storme T; Tang R; Doit C; Tenaillon O; Birgy A
    Sci Rep; 2020 Jan; 10(1):589. PubMed ID: 31953453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of KPC Variant and Porin Genotype on the
    Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.
    Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Snippes Vagnone P; Witwer M; Castanheira M; Johnson JR
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32718965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.
    Gaibani P; Campoli C; Lewis RE; Volpe SL; Scaltriti E; Giannella M; Pongolini S; Berlingeri A; Cristini F; Bartoletti M; Tedeschi S; Ambretti S
    J Antimicrob Chemother; 2018 Jun; 73(6):1525-1529. PubMed ID: 29566151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity.
    Oueslati S; Iorga BI; Tlili L; Exilie C; Zavala A; Dortet L; Jousset AB; Bernabeu S; Bonnin RA; Naas T
    J Antimicrob Chemother; 2019 Aug; 74(8):2239-2246. PubMed ID: 31127297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
    Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A
    Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the NG-Test Carba 5, Colloidal Gold Immunoassay (CGI) Test, and Xpert Carba-R for the Rapid Detection of Carbapenemases in Carbapenemase-Producing Organisms.
    Gu D; Yan Z; Cai C; Li J; Zhang Y; Wu Y; Yang J; Huang Y; Zhang R; Wu Y
    Antibiotics (Basel); 2023 Feb; 12(2):. PubMed ID: 36830211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.